Jennifer Meldrum’s Post

Good morning LinkedIn!!! :) Register today for the upcoming Ontario Pharmaceutical Marketing Association March vitual event!! Join us as Christina Crowe provides her invaluable insights on this important topic!! Check out all the details below, and click on the link to register!! See you there!! :) #opma #learningtogether #neurodiversity #networking

Please join me at this virtual session that explores the importance of managing neurodiversity in the workplace with Chris+Kris Christina Crowe Kristina Harrison #mentalhealthmatters #mentalhealthatwork

Check this program out Pharma peeps! Having perspective on Neurodiversity is more than a good thing for High-Performing Pharma teams and in this ever changing world of Pharma sales and sales in general for that matter!

What Doctors Want in 2024 Out today the second in our series of insights from the 2024 So What? Research Survey of Australian Doctors, looks at: - Top 7 things doctors want more of from pharma - What's going well and what can be improved - Opportunities to do better without reinventing the wheel - How to get more engagement with HCPs Read here: https://lnkd.in/g5JJrhz7 #marketresearch #healthcareresearch

Title: Developing a Tactical Plan for Key Stakeholder Identification & Engagement: The “Art” behind the Science Successfully identifying and engaging key stakeholders is pivotal for promoting awareness, advocacy, and adoption of innovative therapies in the biotech and pharmaceutical industry. Developing a tactical plan involves conducting a comprehensive landscape analysis to pinpoint influencers and understand their interests. Strategic partnerships are then established with Key Opinion Leaders (KOLs), patient advocacy groups, professional societies, and healthcare centers to foster collaboration and alignment. Tailored engagement strategies are crafted for each stakeholder group, focusing on scientific exchange, educational initiatives, and collaborative research projects. Building meaningful and sustainable relationships through ongoing communication and responsiveness is crucial for long-term success. Leveraging technology and digital platforms enhances outreach and engagement, maximizing impact in a rapidly evolving healthcare landscape. Overall, a strategic approach that leverages insights, relationships, and resources is essential for effective stakeholder engagement and advancing scientific innovation to improve patient outcomes. Read the full article @ https://lnkd.in/effhmq5H

In light of the current #business #environment and #talentshortages, #BestPlacestoWork 2023 #research and #analysis has identified several critical differentiating factors of #leading organizations in #Europe, it includes engaging #leadership, #talent focus, #agility and #community #engagement. This year, the #top 25 companies #demonstrated a #strong #commitment to #diversityandinclusion where more than #95% of employees said that individual differences do not affect the way people are treated within their organisations. Takeda Bristol Myers Squibb McDonald's Servier Servier Pharmaceuticals RebelDot Pluxee MSD AlumierMD deskbird Arctic Dipharma SA Teka Group Adalvo Upp Technologies Ltd Faptic Technology Meridiam Olea Medical - Improved Diagnosis for Life Qarnot MLA Advisory B.Conseil - Financement de l'Innovation🌱First Bank SA Heptasys Group Mēness aptieka Konecta FRIME, S.A.U. #topworkplaces2023 #mostperformingcompanies #bestcompaniestoworkfor

Partnerships can be critical in making advancements across every domain. In the pharma sphere, active collaboration between different stakeholders can help in achieving something tangible. In this context, there is a distinct segment of HCPs called the" collaborators" characterized by being open to actively interacting with pharma companies through multiple channels across a broad spectrum of relevant topics. They are also typically willing to work together with others, fostering partnerships to advance medical knowledge, patient care, and healthcare initiatives. So, accurately identifying and understanding the "collaborators" segment is essential for reps or organizations seeking to engage with HCPs in collaborative projects, partnerships, or initiatives. Is your pharma company looking to build fruitful partnerships with HCPs? Contact us at [email protected] to progress on the path of commercial excellence. #Xcellen #customerengagement #pharma #business #technology #management #HCPcommunication #segment #targeting #communication #information #partnerships

🚀 Calling all innovators! The InnoStars Connect programme is here to revolutionise healthcare innovation across Central Eastern and Southern Europe, and we want your groundbreaking ideas to be part of it! This cross-border collaborative initiative brings together industry leaders, start-ups, SMEs, universities, research institutions, and hospitals to drive meaningful change in healthcare. 🌟 What's in it for you? 🤝 Strategic Pharma Partnerships: Join forces with front-runner pharmaceutical companies Chiesi Group and SYNLAB Italia for unparalleled collaboration and growth opportunities. 💡 Cutting-Edge Challenges: Tackle pressing healthcare issues in early diagnostics, patient care, drug delivery, and rare disease therapy, paving the way for innovative solutions. 🎓 Validating and scaling solutions: Through tailored bootcamps online and offline sessions, in close collaboration with industry experts 💰 Funding Opportunities: Secure potential funding and strategic alliances to turn your innovative ideas into impactful solutions. 🌐 Community Membership: Expand your social capital and tap into EIT Health's extensive network and services. Learn more and apply by June 30: https://lnkd.in/dyZ2xfyj #InnoStarsConnect #CrossBorderCollaboration #OpenInnovation

Zuellig Pharma was honoured to be a part of the 2024 Annual J.P. Morgan Healthcare Conference in San Francisco last week, the largest and most informative healthcare investment symposium in the industry connecting over 8,000 global industry leaders, executives and investors. With an optimistic outlook for 2024, conversations centred around the future of healthcare fuelled by an improving global economy, rising merger and acquisition activity, biopharmas’ increasing focus on key therapeutic areas such as obesity, a growing interest in China and the FDA’s focus on artificial intelligence and data and enterprise transformation.   Our Group CEO John A. Graham shared key insights on the growing Southeast and North Asia region, which represents the world’s third-largest market with a population of 1 billion people, before diving into how Zuellig Pharma connects biopharma companies, healthcare professionals, patients and consumers across the healthcare value chain in the region. In particular, he shed light on how Zuellig Pharma builds strategic commercial partnerships to support companies in attaining market leadership in key therapeutic areas, and leverages technology for our innovative market-leading digital tools and support programmes.   As a leading integrated healthcare solutions company, Zuellig Pharma powers the healthcare ecosystem through our wide range of solutions, from commercialisation and market expansion, distribution, clinical trials and sourcing to contract manufacturing. We look forward to deepening existing strategic partnerships and striking up new collaborations with multinational healthcare leaders in 2024, as we remain focused on our mission of making healthcare more accessible in Asia.   #JPMHC24 #HealthcareTrends #MakingHealthcareMoreAccessible 

Patient communities on social media are untapped goldmines. 💎 👇👇👇 Engaging with and understanding patient communities on social platforms can provide pharma brands with invaluable insights into patient needs and experiences. 1️⃣ Direct Insights into Patient Needs: Engaging with patient communities on social media offers pharma companies direct insight into patient experiences, concerns, and treatment outcomes. 2️⃣ Opportunity for Engagement and Support: These platforms provide an opportunity for pharma companies to engage in two-way communication, offering support, answering questions, and gathering feedback. 3️⃣ Research and Development Implications: Insights from patient communities can inform drug development and marketing strategies, making them more patient-centric. 4️⃣ Ethical Considerations: Engaging with these communities requires sensitivity and ethical consideration, ensuring that interactions are supportive and not solely commercially driven.